Precision BioSciences (DTIL)
6.50
+0.09 (1.40%)
Upcoming Events
Latest Headlines
Form 4 PRECISION BIOSCIENCES For: Jun 03 Filed by: Brown Melinda
June 5, 2026 7:39 AM - SEC Filing
Form 4 PRECISION BIOSCIENCES For: Jun 03 Filed by: Frankel Stanley
June 5, 2026 7:38 AM - SEC Filing
Form 4 PRECISION BIOSCIENCES For: Jun 03 Filed by: Germano Geno J
June 5, 2026 7:37 AM - SEC Filing
Form 4 PRECISION BIOSCIENCES For: Jun 03 Filed by: Pire Shari Lisa
June 5, 2026 7:36 AM - SEC Filing
Form 4 PRECISION BIOSCIENCES For: Jun 03 Filed by: Buehler Kevin
June 5, 2026 7:35 AM - SEC Filing
Form 4 PRECISION BIOSCIENCES For: Jun 01 Filed by: SMITH J. JEFFERSON
June 3, 2026 4:07 PM - SEC Filing
Form 4 PRECISION BIOSCIENCES For: Jun 01 Filed by: Scimeca Dario
June 3, 2026 4:06 PM - SEC Filing
Form 4 PRECISION BIOSCIENCES For: Jun 01 Filed by: Kelly John Alexander
June 3, 2026 4:06 PM - SEC Filing
Form 4 PRECISION BIOSCIENCES For: Jun 01 Filed by: Amoroso Michael
June 3, 2026 4:05 PM - SEC Filing
Form 8-K PRECISION BIOSCIENCES For: May 27
May 27, 2026 7:31 AM - SEC Filing
Precision BioSciences reports hepatitis B gene therapy data from clinical trial
May 27, 2026 4:05 AM - StreetInsider
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
May 27, 2026 2:30 AM - BizWire
Form 8-K PRECISION BIOSCIENCES For: May 21
May 26, 2026 5:20 PM - SEC Filing
Form 4 PRECISION BIOSCIENCES For: May 20 Filed by: Buehler Kevin
May 22, 2026 7:32 AM - SEC Filing
Form 4 PRECISION BIOSCIENCES For: May 20 Filed by: Frankel Stanley
May 22, 2026 7:31 AM - SEC Filing
Form 4 PRECISION BIOSCIENCES For: May 20 Filed by: Brown Melinda
May 22, 2026 7:31 AM - SEC Filing
Form 4 PRECISION BIOSCIENCES For: May 20 Filed by: Pire Shari Lisa
May 22, 2026 7:31 AM - SEC Filing
Form 4 PRECISION BIOSCIENCES For: May 20 Filed by: Germano Geno J
May 22, 2026 7:30 AM - SEC Filing
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
May 21, 2026 7:01 AM - BizWire
iECURE reports positive results from gene therapy trial for rare disorder
May 18, 2026 8:02 AM - StreetInsider
iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-5
May 18, 2026 8:00 AM - BizWire
Precision BioSciences reports enhanced DMD gene therapy efficacy in younger mice
May 14, 2026 7:01 AM - StreetInsider
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
May 14, 2026 7:01 AM - BizWire
iECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual Meeting
May 13, 2026 6:00 AM - BizWire
Precision BioSciences (DTIL) Misses Q1 EPS by 75c
May 5, 2026 10:22 AM - StreetInsider
Form 10-Q PRECISION BIOSCIENCES For: Mar 31
May 5, 2026 7:20 AM - SEC Filing
Form 8-K PRECISION BIOSCIENCES For: May 05
May 5, 2026 7:19 AM - SEC Filing
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 5, 2026 7:01 AM - BizWire
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
April 30, 2026 7:01 AM - BizWire
Precision BioSciences begins patient enrollment in DMD gene editing trial
April 29, 2026 7:01 AM - StreetInsider
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
April 29, 2026 7:01 AM - BizWire
iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual Meetings
April 28, 2026 8:02 AM - BizWire
Precision BioSciences to present DMD gene therapy data at ASGCT 2026
April 28, 2026 7:01 AM - StreetInsider
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
April 28, 2026 7:01 AM - BizWire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 24, 2026 7:01 AM - BizWire
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
April 22, 2026 7:01 AM - BizWire
Jones Trading Assumes Precision BioSciences Inc. (DTIL) at Buy
April 16, 2026 4:08 PM - StreetInsider
Form SCHEDULE 13G/A PRECISION BIOSCIENCES Filed by: Empery Asset Management, LP
April 15, 2026 9:46 AM - SEC Filing
Precision BioSciences expands hepatitis B trial to France and Romania
April 15, 2026 7:02 AM - StreetInsider
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
April 15, 2026 7:01 AM - BizWire
Form ARS PRECISION BIOSCIENCES For: Dec 31
April 8, 2026 7:02 AM - SEC Filing
Form DEFA14A PRECISION BIOSCIENCES
April 8, 2026 7:02 AM - SEC Filing
Form DEF 14A PRECISION BIOSCIENCES For: May 21
April 8, 2026 7:01 AM - SEC Filing
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026 7:01 AM - BizWire
Form PRE 14A PRECISION BIOSCIENCES For: May 21
March 27, 2026 4:06 PM - SEC Filing
Jones Trading stays Buy on Precision BioSciences Inc. (DTIL) following Ph1/2 trial design announcement
March 18, 2026 9:07 AM - StreetInsider
iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission
March 18, 2026 8:00 AM - BizWire
Form 8-K PRECISION BIOSCIENCES For: Mar 17
March 17, 2026 8:32 AM - SEC Filing
Precision BioSciences Inc. (DTIL) PT Lowered to $19 at Jefferies, but 'near-term setup is attractive'
March 13, 2026 2:57 PM - StreetInsider
Precision BioSciences (DTIL) Tops Q4 EPS by 105c
March 12, 2026 8:36 AM - StreetInsider
Form 10-K PRECISION BIOSCIENCES For: Dec 31
March 12, 2026 7:32 AM - SEC Filing
Form 8-K PRECISION BIOSCIENCES For: Mar 12
March 12, 2026 7:31 AM - SEC Filing
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
March 12, 2026 7:00 AM - BizWire
Precision BioSciences receives patent allowances for HBV gene editing program
March 11, 2026 7:01 AM - StreetInsider
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
March 11, 2026 7:01 AM - BizWire
Precision BioSciences shows muscle improvements in DMD gene therapy study
March 10, 2026 7:01 AM - StreetInsider
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference
March 10, 2026 7:01 AM - BizWire
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026
March 9, 2026 4:15 PM - BizWire
Precision BioSciences gets FDA fast track for DMD gene therapy
March 9, 2026 7:01 AM - StreetInsider
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
March 9, 2026 7:01 AM - BizWire
Full Article List